Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
about
HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physiciansThe Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Dual-color plasmonic enzyme-linked immunosorbent assay based on enzyme-mediated etching of Au nanoparticles.
P2860
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Performance of a redesigned HI ...... IV vaccine trial participants.
@en
Performance of a redesigned HI ...... IV vaccine trial participants.
@nl
type
label
Performance of a redesigned HI ...... IV vaccine trial participants.
@en
Performance of a redesigned HI ...... IV vaccine trial participants.
@nl
prefLabel
Performance of a redesigned HI ...... IV vaccine trial participants.
@en
Performance of a redesigned HI ...... IV vaccine trial participants.
@nl
P2093
P2860
P50
P356
P1476
Performance of a redesigned HI ...... IV vaccine trial participants.
@en
P2093
Andrew E Levin
David Clapham
David Crane
Eric Hunter
HIV Selectest Study Group
Isaac R Rodriguez-Chavez
John Hural
Keith Higgins
Neil X Krueger
Oksana Penezina
P2860
P304
P356
10.1128/CVI.00748-13
P577
2014-01-08T00:00:00Z